Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New computer test could spot MS brain fog faster

NCT ID NCT02391064

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a short, computerized cognitive assessment in 421 French-speaking adults with multiple sclerosis and healthy controls. The goal was to see if a brief battery of computer tests can reliably detect early cognitive issues, like slowed thinking and memory problems, compared to a longer standard battery. If validated, this could make cognitive screening quicker and more accessible in routine MS care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide a quick, reliable way to screen for cognitive problems in MS patients, helping doctors monitor the disease more easily.
What could go wrong
This is a validation study, not a treatment trial. The new test may not be as accurate as existing methods, and results may not apply to all MS types or languages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

421 people

The number who actually took part.

Started

Feb 2015

Finished

Feb 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients : * Aged 18-64 years * Francophone * MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms * Having signed an informed consent (later than the day of inclusion and before any examination required by research) * Being affiliated to health insurance Controls: * Aged 18-64 years * Francophone * Having signed an informed consent (later than the day of inclusion and before any examination required by research) * Being affiliated to health insurance Exclusion Criteria: Patients: * Other neurological diseases with impact on cognitive functions. * Severe psychiatric disease or severe depression. * Current Dependence on alcohol or drugs. * Modification or stop of psychotropic treatment in less than a month. * Modification of MS treatment in less than a month. * Visual, visual-motor and / or motor impairments excluding the ability to perform cognitive tests. * Pregnant Controls: * Neurologic disease and known chronic systemic with impact on cognitive functions. * Severe psychiatric disease or severe depression. * Current Dependence on alcohol or drugs. * Psychotropic treatment * Cognitive complaint * Prior cognitive testing with the same tests less than one year. * Pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • CH de Dunkerque

    Dunkirk, 59385, France

  • CHU Montpellier

    Montpellier, 34295, France

  • CHU de Bordeaux

    Bordeaux, 33000, France

  • CHU de Caen

    Caen, 14033, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63003, France

  • CHU de Marseille

    Marseille, 13385, France

  • CHU de Nancy

    Nancy, 54035, France

  • CHU de Nice

    Nice, 06002, France

  • CHU de Reims

    Reims, 51092, France

  • CHU de Strasbourg

    Strasbourg, 67200, France

  • Centre Hospitalier Saint Vincent de Paul

    Lille, 59020, France

  • Hôpital Roger Salengro

    Lille, France

  • Hôpital Tenon

    Paris, 75970, France

  • Hôpital de Poissy Saint Germain

    Poissy, 78303, France

  • Hôpital du Bocage

    Dijon, 21079, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.